Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis

Primary Glomerulonephritis Clinical Trial

Official title:

Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00154661
• Other study ID #: 152S2
• Status: Completed
• Phase: N/A
• First received: September 8, 2005
• Last updated: September 8, 2005
• Start date: January 2000
• Est. completion date: June 2001

Study information

• Verified date: June 2001
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Interventional

Clinical Trial Summary

we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis.

Description:

Pentoxifylline (PTX) is a phosphodiesterase inhibitor that is widely used for the treatment of peripheral vascular occlusive disorders. In addition, PTX has shown its ability to attenuate nephrotic syndrome secondary to membranous glomerulonephritis and lupus nephritis, and to reduce subnephrotic proteinuria due to early and advanced diabetic nephropathy. However, data with respect to its effect on non-nephrotic primary glomerular diseases are lacking. Moreover, while the anti-proteinuric effect of PTX has been largely attributed to down-regulation of TNF-a, it remains unknown whether other mediators, especially MCP-1, are also affected by PTX. Because our previous works have shown that PTX attenuates proteinuria and suppresses renal MCP-1 mRNA expression in experimental glomerulonephritis in rats, we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis. This study was thereby conducted to investigate the potential anti-proteinuric and anti-MCP-1 effects of PTX in subnephrotic patients with primary glomerular diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 2001
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

• glomerular diseases with subnephrotic proteinuria

Exclusion Criteria:

• DM, hepatitis, systemic immunologic renal diseases

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glomerulonephritis
• Primary Glomerulonephritis

Intervention

Drug:
• pentoxifylline

Locations

Country	Name	City	State
Taiwan	Yung-Ming Chen	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	proteinuria
Secondary	inflammatory mediators